IPHASE Ua kom tiav FDA Kev Sau Npe Ntshav los txhawb Biopharma Excellence
IPHASE zoo siab tshaj tawm txog qhov ua tiav ntawm xyoo no FDA Cov Ntshav Tsim Kev Sau Npe, txhawb nqa peb txoj kev cog lus rau kev ua raws cai, zoo, thiab biopharma - npaj ua haujlwm.
Raws li FDA cov cai (21 CFR 607), cov chaw tsim khoom koom nrog hauv kev tsim cov ntshav thiab ntshav - cov khoom tau los yuav tsum tau sau npe nrog lub koom haum thiab sau cov khoom siv. Qhov kev tso npe no lees paub tias peb lub chaw ua tau raws li FDA cov cai rau kev tsim thiab tuav cov ntshav thiab cov ntshav - cov khoom tau los. Rau cov neeg koom tes biopharmaceutical, qhov no txhais ua kev ntseeg siab hauv qhov zoo, traceability, thiab kev tswj hwm kev ruaj khov ntawm cov ntaub ntawv biomatrix txhawb kev tshawb fawb txog kev tshawb fawb, kev tsim kho, thiab kev siv hauv qab.
Ntawm IPHASE, kev ua raws cai yog tsim rau hauv txhua kauj ruam ntawm peb cov txheej txheem. Peb tseem mob siab rau muab cov kev daws teeb meem zoo ib yam, txhim khu kev qha, thiab siab - zoo biomatrix cov kev daws teeb meem uas pab pawg biopharma txav nrawm dua-los ntawm kev tshawb pom los ntawm kev txhim kho-thaum lub rooj sib tham evolving regulatory expectations.
Hnub tim: 2026-01-27 16:37:06